208 related articles for article (PubMed ID: 21861932)
1. Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.
Singh PP; Joshi S; Russell PJ; Nair S; Khatri A
BMC Cancer; 2011 Aug; 11():368. PubMed ID: 21861932
[TBL] [Abstract][Full Text] [Related]
2. Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer.
Singh PP; Joshi S; Russell PJ; Verma ND; Wang X; Khatri A
Clin Cancer Res; 2011 Jun; 17(12):4006-18. PubMed ID: 21531822
[TBL] [Abstract][Full Text] [Related]
3. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer.
Martiniello-Wilks R; Wang XY; Voeks DJ; Dane A; Shaw JM; Mortensen E; Both GW; Russell PJ
J Gene Med; 2004 Dec; 6(12):1343-57. PubMed ID: 15493036
[TBL] [Abstract][Full Text] [Related]
4. In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.
Sorscher EJ; Hong JS; Allan PW; Waud WR; Parker WB
Cancer Chemother Pharmacol; 2012 Aug; 70(2):321-9. PubMed ID: 22760227
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models.
Voeks D; Martiniello-Wilks R; Madden V; Smith K; Bennetts E; Both GW; Russell PJ
Gene Ther; 2002 Jun; 9(12):759-68. PubMed ID: 12040457
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.
Wang XY; Martiniello-Wilks R; Shaw JM; Ho T; Coulston N; Cooke-Yarborough C; Molloy PL; Cameron F; Moghaddam M; Lockett TJ; Webster LK; Smith IK; Both GW; Russell PJ
Gene Ther; 2004 Nov; 11(21):1559-67. PubMed ID: 15343359
[TBL] [Abstract][Full Text] [Related]
7. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells.
Gadi VK; Alexander SD; Kudlow JE; Allan P; Parker WB; Sorscher EJ
Gene Ther; 2000 Oct; 7(20):1738-43. PubMed ID: 11083495
[TBL] [Abstract][Full Text] [Related]
8. Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase.
Guillen KP; Kurkjian C; Harrison RG
J Biomed Sci; 2014 Jul; 21(1):65. PubMed ID: 25047949
[TBL] [Abstract][Full Text] [Related]
9. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease.
Martiniello-Wilks R; Dane A; Voeks DJ; Jeyakumar G; Mortensen E; Shaw JM; Wang XY; Both GW; Russell PJ
J Gene Med; 2004 Jan; 6(1):43-54. PubMed ID: 14716676
[TBL] [Abstract][Full Text] [Related]
10. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors.
Martiniello-Wilks R; Garcia-Aragon J; Daja MM; Russell P; Both GW; Molloy PL; Lockett LJ; Russell PJ
Hum Gene Ther; 1998 Jul; 9(11):1617-26. PubMed ID: 9694160
[TBL] [Abstract][Full Text] [Related]
11. Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene.
Hong JS; Waud WR; Levasseur DN; Townes TM; Wen H; McPherson SA; Moore BA; Bebok Z; Allan PW; Secrist JA; Parker WB; Sorscher EJ
Cancer Res; 2004 Sep; 64(18):6610-5. PubMed ID: 15374975
[TBL] [Abstract][Full Text] [Related]
12. An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression.
Blumenthal RD; Leone E; Goldenberg DM; Rodriguez M; Modrak D
Int J Cancer; 2004 Jan; 108(2):293-300. PubMed ID: 14639618
[TBL] [Abstract][Full Text] [Related]
13. Suicide gene/prodrug therapy for pancreatic adenocarcinoma by E. coli purine nucleoside phosphorylase and 6-methylpurine 2'-deoxyriboside.
Deharvengt S; Wack S; Uhring M; Aprahamian M; Hajri A
Pancreas; 2004 Mar; 28(2):E54-64. PubMed ID: 15028961
[TBL] [Abstract][Full Text] [Related]
14. Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?
Nawa A; Tanino T; Luo C; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Nishiyama Y; Kikkawa F
Anticancer Agents Med Chem; 2008 Feb; 8(2):232-9. PubMed ID: 18288924
[TBL] [Abstract][Full Text] [Related]
15. Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy.
Krais JJ; De Crescenzo O; Harrison RG
PLoS One; 2013; 8(10):e76403. PubMed ID: 24098491
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin-specific transcription and splicing targets gene-directed enzyme prodrug therapy to medullary thyroid carcinoma cells.
Messina M; Yu DM; Both GW; Molloy PL; Robinson BG
J Clin Endocrinol Metab; 2003 Mar; 88(3):1310-8. PubMed ID: 12629124
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1.
Liu E; Liu Z; Zhou Y
Int J Clin Exp Pathol; 2015; 8(4):3803-10. PubMed ID: 26097562
[TBL] [Abstract][Full Text] [Related]
18. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
19. Evaluating antitumor activity of Escherichia coli purine nucleoside phosphorylase against head and neck patient-derived xenografts.
Rab R; Ehrhardt A; Achyut BR; Joshi D; Gilbert-Ross M; Huang C; Floyd K; Borovjagin AV; Parker WB; Sorscher EJ; Hong JS
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1708. PubMed ID: 36253876
[TBL] [Abstract][Full Text] [Related]
20. Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts.
Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
Cancer Gene Ther; 2007 Mar; 14(3):279-86. PubMed ID: 17218950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
